Neoplastic meningitis: a unique disease process or a 'test tube' for evaluating cancer treatments?
Improved treatment of systemic cancers has prolonged the lives of many patients but has also led to increased incidence of neoplastic meningitis. The prognosis for patients who develop neoplastic meningitis or leptomeningeal dissemination of cancer cells remains poor. This paper reviews the pathologic reasons for this poor prognosis, describes recent research in animal models that explores new therapies, and discusses the potential of these new treatment possibilities for clinical use in the context of the associated biology and pathology. The author provides an overview of the accompanying articles for the Neuro-Oncology section, which explore the mechanisms leading to neoplastic meningitis, the role of radiotherapy and chemotherapy in this disease process, and the toxicities of treatment.
Gilbert
Mark R
MR
Department of Clinical Neuro-Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0100, Houston, TX 77030, USA. mrgilbert@mdanderson.org
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D008577:Meningeal Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000556:secondary; D008581:Meningitis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D023421:Models, Animal
D000970:Antineoplastic Agents